Submissions

Guide for Authors

• Article Publishing Fee (APC)
• Preparing to Submit
• Pre-Submission Checklist
• Editorial Policies
• Open Access Licenses
• Use of Artifical Intelligence
• Corrections and Retractions
• Ethics
• Editorial and Peer Review Process
• Article Types
  • Original Research
  • Short Report
  • Review
  • Mini-Review
  • Case Study
  • Inspirational Profile
  • Editorial
• Document Format
• Content Format
• Content Order
• Content Detail
  • Introduction
  • Methods
  • Results
  • Discussion
  • Acknowledgements
  • Conflicts of Interest
  • CRediT
  • Data Availability Statement
  • Ethics Statement
  • Funding Sources
  • Funding Influence
  • Supplementary Material
  • References
• Tier System
• Fundamental Style & Grammatical Guidance
• Standard Abbreviations

https://politicalphilosophyjournal.org/site/author-guidelines/

MICROSOFT WORD: For typesetting purposes, the author must submit final copy in the form of a Microsoft Word document.

Article Publishing Fee (APC)

There is no APC for MSACL members who are either the first or last author. Non-members are required to pay the fee shown in the table below. JMSACL follows tiered pricing based on country of residence.

MSACL Member	Non-Member
USD 0	A: USD 2,200 B: USD 1,400 C: USD 690 D: USD 0

>A: Original Research, Review, Inspirational Profile (if uninvited) >B: Mini-Review, Short Report, Case Study >C: Editorial >D: Correction

Preparing to Submit

Pre-Submission Checklist

Before you submit, please download and complete this [Pre-Submission Checklist](https://www.msacl.org/JMSACL_PRE-SUBMISSION_CHECKLIST.php) to verify you are not missing any key components or formatting requirements.

Submission Declaration

When authors submit an article to JMSACL it is implied that:

• the work described has not been published previously except in the form of a preprint, an abstract, a published lecture, academic thesis or registered report.
• the article is not under consideration for publication elsewhere.
• the article's publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.
• if accepted, the article will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

To verify compliance with our journal publishing policies, we may check your manuscript with our screening tools.

Additional Documents Needed

These additional documents will need to be completed and included with your submission. - [Conflict of Interest Worksheet](https://www.msacl.org/JMSACL_COI.php) - [Ethics and IRB Worksheet](https://www.msacl.org/JMSACL_ETHICS_IRB.php)

Obtain Permission for Copyrighted Works

If excerpts from other copyrighted works are included in your article, you must obtain written permission from the copyright owners and credit the source(s) within your article using JMSACL’s permission request and license form (Word). _this document is under JMSACL>scholastica_

Cover Letter

A cover letter is NOT required for NEW submissions. For REVISED submissions, a cover letter should summarize any changes made to the manuscript based on the authors' own initiative or in response to reviewer comments.

Suggesting Reviewers

You are not required or able to suggest reviewers.

Editorial Policies

Open Access

The Journal of Mass Spectrometry and Advances in the Clinical Lab (JMSACL) is a fully open access journal. All articles immediately and permanently free for everyone to read and download, copy and distribute.

Licenses

We offer authors a choice of user licenses, which define the permitted reuse of articles.

1. Creative Commons Attribution (CC BY)
   • Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); includes a link to the license; indicates if changes were made; and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
2. Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
   • Allows users to: distribute and copy the article; and include in a collective work (such as an anthology). These uses are permitted only for non-commercial purposes, and provided the user: gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); provides a link to the license; and does not alter or modify the article.
3. Creative Commons Attribution-ShareAlike (CC BY-SA)
   • Allows individuals to share, remix, and build upon a work, provided they give appropriate credit to the original creator and indicate if any changes were made. This license requires that any derivative works be distributed under the same or a compatible license, ensuring that future adaptations remain accessible under the same terms while permitting both commercial and non-commercial use. By promoting attribution and the sharing of modified works, CC BY-SA fosters a collaborative environment that encourages creativity and innovation, all while safeguarding the rights of the original authors.

Peer Review

JMSACL is peer-reviewed. We follow a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will be taken by our editors. The editorial decision is final. Reviewers are encouraged to be familiar with the document [Ethical Guidelines for Peer Reviewers](https://publicationethics.org/sites/default/files/ethical-guidelines-peer-reviewers-cope.pdf) published by COPE. When reviewers agree to assess a paper, we consider this a commitment to review subsequent revisions. However, editors will not send a resubmitted paper back to the reviewers if it seems that the authors have not made a serious attempt to address the criticisms. Our editors are NOT involved in making decisions about papers which:

• they have written themselves.
• have been written by family members or colleagues.
• relate to products or services in which they have an interest.

Any such submissions will be subject to the journal's usual procedures and peer review will be handled independently of the editor involved and their research group.

Special Issues and Article Collections

The peer review process for special issues and article collections follows the same process as outlined above for regular submissions, except, a GUEST editor will send the submissions out to the reviewers and may recommend a decision to the journal editor. The journal editor oversees the peer review process of all special issues and article collections to ensure the standards of publishing ethics and responsiveness are respected and is responsible for the final decision regarding acceptance or rejection of articles.

Authorship

Authors are expected to fulfil the criteria presented in [Transparency in authors’ contributions and responsibilities to promote integrity in scientific publication](https://www.pnas.org/content/115/11/2557). Each author is expected to have:

• made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; or have drafted the work or substantively revised it
• approved the submitted version (and any substantially modified version that involves the author's contribution to the study);
• agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

JMSACL reserves the right not to consider non-primary research manuscripts that have been authored by medical writers. Writing assistance should be acknowledged in all article types. At submission, the corresponding author must include written permission from the authors for mention of any unpublished material cited in the manuscript (e.g., others' data, in press manuscripts, personal communications or work in preparation). The corresponding author also must clearly identify at submission any material within the manuscript (such as figures) that has been published previously elsewhere and provide written permission from authors of the prior work and/or publishers, as appropriate, for the re-use of such material. After acceptance, the corresponding author is responsible for the accuracy of all content in the proof, including the names of co-authors, addresses and affiliations. After publication, the corresponding author is the point of contact for queries about the published paper. It is their responsibility to inform all co-authors of any matters arising in relation to the published paper and to ensure such matters are dealt with promptly. Authors of published material have a responsibility to inform the journal immediately if they become aware of any aspects that requires correction. Any changes to the author list after submission, such as a change in the order of the authors or the deletion or addition of authors, must be approved by every author. Changes of authorship by adding or deleting authors, and/or changes in Corresponding Author, and/or changes in the sequence of authors are not permitted after acceptance of a manuscript. To improve transparency and unambiguous attribution of scholarly contributions, corresponding authors of published papers must provide their Open Researcher and Contributor Identifier (ORCID); co-authors are encouraged to provide their ORCiD. For transparency, JMSACL requires corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. All authors agree to be accountable for all aspects of the work to ensure that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Changes to Authorship

The editors of this journal generally will not consider changes to authorship once a manuscript has been submitted. It is important that authors carefully consider the authorship list and order of authors and provide a definitive author list at original submission. The policy of this journal around authorship changes: - All authors must be listed in the manuscript and their details entered into the submission system. - Any addition, deletion or rearrangement of author names in the authorship list should only be made prior to acceptance, and only if approved by the journal editor. - Requests to change authorship should be made by the corresponding author, who must provide the reason for the request to the journal editor with written confirmation from all authors, including any authors being added or removed, that they agree with the addition, removal or rearrangement. - Only in exceptional circumstances will the journal editor consider the addition, deletion or rearrangement of authors post acceptance. - Publication of the manuscript may be paused while a change in authorship request is being considered. - Any authorship change requests approved by the journal editor will result in a corrigendum if the manuscript has already been published. - Requests to change the corresponding author to qualify for Read and Publish funding will not be accepted.

Conflicts of Interest

Application to Authors

We require that all submissions include a [Conflicts of Interest (COI) worksheet](https://www.msacl.org/JMSACL_COI.php) with information for all authors on any related interests, including financial interests that might be perceived as relevant. The authors are required to include these declarations in the final published paper towards the end of the document in a section entitled "Conflicts of Interest".

Application to Reviewers

We require that all peer-reviewers inform the editors of any related interests, including financial interests that might be perceived as relevant. Editors will consider these statements when weighing reviewers' recommendations.

Application to Editors

All journal editorial staff are required to declare to any interests — financial or otherwise — that might influence, or be perceived to influence, their editorial practices.

Application to Publishing Policy

JMSACL's strict policy is that editorial independence, decisions and content should not be compromised by commercial or financial interests, or by any specific arrangements with advertising clients or sponsors. Our policy is to disclose such arrangements if there is any risk of a perception of compromise.

Image Manipulation

Digital images submitted with a manuscript for review should be minimally processed. A certain degree of image processing is acceptable for publication, but the final image must correctly represent the original data and conform to community standards. Any manipulation of images for the purpose of deception or fraud will be seen as scientific ethical abuse. Editors may use software to screen images for manipulation. Authors must adhere to this journal’s policy for graphical images: - No specific feature within an image may be enhanced, obscured, moved, removed or introduced. - Adjustments of brightness, contrast, or color balance are acceptable if, and only as long as, they do not obscure or eliminate any information present in the original image. - Nonlinear adjustments such as changes to gamma settings MUST be disclosed in the figure legend. - We do not permit the use of generative AI or AI-assisted tools to create or alter images in submitted manuscripts. To verify compliance with the above, this journal may send your images to a third-party service who screen for image irregularities. Our editors may ask you to provide original data or images if any questions arise as a result of the screening. The final decision as to whether images are acceptable will be taken by our editors. Authors are encouraged to carefully check all images before submission and to connect all the data in any figures to the original, unprocessed data.

Original Image Requests and Retention

Editors may request the unprocessed data files to help in manuscript evaluation during the peer review process; if these data are unavailable upon request, we may need to halt the peer review process until the issues are satisfactorily resolved. We may also request unprocessed data when responding to post-publication issues that may arise with published papers. We recommend retaining unprocessed data and metadata files after publication, ideally archiving data in perpetuity.

Use of Artificial Intelligence (AI)

Scientific Writing

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, application of the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans.

Language Editting

Use of language editing services, AI or human, is recommended to improve the quality of your submission. AI models are effective at improving grammar and identifying errors for those who do not have a strong mastery of the English language.

Image Creation or Manipulation

The use of Generative AI or AI-assisted tools to create or alter images in submitted manuscripts is NOT permitted. The only exception is if the use of AI or AI-assisted tools is part of the research design or methods (for example, in the field of biomedical imaging). If this is the case, such use must be described in a reproducible manner in the methods section, including the name of the model or tool, version and extension numbers, and manufacturer. The use of generative AI in the production of cover art may in some cases be allowed, if the author obtains prior permission from the journal editor and publisher, can demonstrate that all necessary rights have been cleared for the use of the relevant material, and ensures that there is correct content attribution. The use of generative AI or AI-assisted tools in the production of artwork such as for graphical abstracts is not permitted. The use of generative AI in the production of cover art may in some cases be allowed, if the author obtains prior permission from the journal editor and publisher, can demonstrate that all necessary rights have been cleared for the use of the relevant material, and ensures that there is correct content attribution.

Overlapping Submissions to Other Journals

When you submit a manuscript to JMSACL its content must not significantly overlap with any other papers from you or your co-authors’ groups that are under consideration or in press at other journals, not including conference abstracts or preprints.

Preprints

JMSACL encourages posting of preprints of original research manuscripts on preprint servers of the authors’ choice, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Preprints are defined as an author’s version of a research manuscript prior to formal peer review at a journal, which is deposited on a public server (as described in [Preprints for the life sciences. Science 352, 899–901; 2016](https://www.science.org/doi/10.1126/science.aaf9133)); preprints may be posted at any time during the peer review process. Posting of preprints is not considered prior publication and will not jeopardize consideration at JMSACL. Authors should disclose details of preprint posting, including DOI and licensing terms, upon submission of the manuscript or at any other point during consideration at JMSACL. Once the preprint is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Authors may choose any license of their choice for the preprint including Creative Commons licenses. The type of CC-license chosen will affect how the preprint may be shared and reused.

Post-Acceptance Copyediting

It is important that the final journal output to the readership is clear, consistent, devoid of as many errors as possible, as well as being scientifically sound. The editors and reviewers generally do not have time to help the authors bring the manuscript to a final "polish"; hence, once it is scientifically approved it undergoes a more fine-grained evaluation of the grammatical, stylistic and scientific details. The goal of this post-acceptance copy editting is to provide content that is more likely to be respected and cited, increasing the value of the journal, and, thereby, each paper in the journal.

Post-Acceptance Rejection

Following acceptance of your manuscript JMSACL reserves the right to decline publication of a paper even after it has been accepted if it becomes apparent that there are serious problems with the scientific content or violations of our publishing policies.

Removal of Published Content

In exceptional circumstances, JMSACL reserves the right to remove an article or other content from JMSACL online platforms. Such action may be taken when (i) JMSACL has been advised that content is defamatory, infringes a third party’s intellectual property right, right to privacy, or other legal right, or is otherwise unlawful; (ii) a court or government order has been issued, or is likely to be issued, requiring removal of such content; (iii) content, if acted upon, would pose an immediate and serious risk to health. Removal may be temporary or permanent. Bibliographic metadata (e.g., title and authors) will be retained, and will be accompanied by a statement explaining why the content has been removed.

Corrections & Retractions

JMSACL will only make changes to published papers if the publication record is seriously affected by the academic accuracy of the published information. Any correction will have a separately published notice describing the changes to maintain the transparency of the scholarly record. The notice will be published online at the earliest opportunity and will be clearly linked to the Version of Record. A link will also appear on the Version of Record, notifying readers that a post-publication change has been published. As needed, we follow the [COPE guidelines on retractions](https://publicationethics.org/retraction-guidelines). Changes that are needed to content published within the last 12 months will be made directly to the original, where possible. Any changes to older content will be explained in the linked notice only, with the exception of author name changes. The following are categories of corrections and post-publication updates to peer-reviewed original research and review articles and certain kinds of non-peer reviewed article types. Substantial errors to Supplementary Information and Extended Data are corrected in the same manner as amendments to the main article. With the exception of Editor’s Notes, all categories below are bi-directionally linked to the original article and indexed. >JMSACL includes the **CrossMark button** on the HTML and online PDFs of all articles. CrossMark is an industry standard mechanism that allows readers to quickly check that the version of the article they are reading is up-to-date. By clicking the CrossMark button readers can view the CrossMark record for that article, with details of all formal amendments and corrections. **Author Correction:** An Author Correction may be published to correct an important error(s) made by the author(s) that affects the scientific integrity of the published article, the publication record, or the reputation of the authors or the journal. **Author Name Change:** For authors who’ve changed their name and wish to correct it on their published works, please see below. **Publisher Correction:** A Publisher Correction may be published to correct an important error(s) made by the journal that affects the scientific integrity of the published article, the publication record, or the reputation of the authors or of the journal. **Addendum:** An addendum is generally published when significant additional information crucial to the reader’s understanding of the article has come to light following publication of the article. **Editor's Note:** An Editor's Note is a notification alerting readers if the journal has initiated an inquiry in response to concerns raised about a published article. It is an online-only update, made only to the HTML version of record of the published article. It is not indexed. **Editorial Expression of Concern:** An Editorial Expression of Concern is a statement from the editors alerting readers to serious concerns affecting the integrity of the published paper. EEoCs are published online and are bidirectionally linked to the published paper. They receive a DOI and are indexed in major scholarly databases such as PubMed, Web of Science and Scopus. EEoCs may be an interim measure or may be final. Publishing an Editor’s Note or EEoC is recommended by the [Committee on Publication Ethics (COPE)](https://publicationethics.org/retraction-guidelines) as a means of keeping readers updated while a potentially lengthy research integrity investigation is underway. Editor’s Notes and EEoCs are typically superseded by publishing another amendment-such as a correction or retraction-once the investigation is complete. **Retraction:** An article may be retracted when the integrity of the published work is substantially undermined owing to errors in the conduct, analysis and/or reporting of the study. Violation of publication or research ethics may also result in a study’s retraction. The original article is marked as retracted but a PDF version remains available to readers, and the retraction statement is bi-directionally linked to the original published paper. Retraction statements will typically include a statement of assent or dissent from the authors. When making corrections to articles, in the majority of cases the original article (PDF and HTML) is corrected and is bi-directionally linked to and from the published amendment notice, which details the original error. For the sake of transparency, when changes made to the original article affect data in figures, tables or text (for example, when data points/error bars change or curves require redrawing) the amendment notice will reproduce the original data. When it is not possible to correct the original article in both HTML and PDF versions (for example, articles published many years before the error is raised) the article will remain unchanged but will contain bi-directional links to and from the published amendment notice.

Digital Object Identifier (DOI)

A Digital Object Identifier (DOI) is allocated to each publication making it fully citable and searchable by title, author name(s) and the full text.

Digital Archiving

All published manuscripts are digitally archived through the [CLOCKSS](https://clockss.org/join-academic-publishers/) program.

CrossMark

[CrossMark](https://www.crossref.org/services/crossmark/) is a multi-publisher initiative to provide a standard way for readers to locate the current version of a piece of content. By applying the CrossMark logo JMSACL is committed to maintaining the content it publishes and to alerting readers to changes if and when they occur. Clicking on the CrossMark logo will tell you the current status of a document and may also give you additional publication record information about the document.

Ethics

Use of Inclusive Language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Authors should ensure that their work uses inclusive language throughout and contains nothing which might imply one individual is superior to another on the grounds of: - age - gender - race - ethnicity - culture - sexual orientation - disability or health condition We recommend avoiding the use of descriptors about personal attributes unless they are relevant and valid. Write for gender neutrality with the use of plural nouns ("clinicians, patients/clients") as default. Wherever possible, avoid using "he, she," or "he/she." No assumptions should be made about the beliefs of readers and writing should be free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. These guidelines are meant as a point of reference to help you identify appropriate language but are by no means exhaustive or definitive.

Studies in Humans and Animals

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association (Declaration of Helsinki)](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](http://www.icmje.org/recommendations/) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](https://www.who.int/gender-equity-rights/understanding/gender-definition/en/) should be used correctly. The author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the appropriate institutional committee(s). This statement should contain the date and reference number of the ethical approval(s) obtained. Authors should also include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. The journal will not accept manuscripts that contain data derived from unethically sourced organs or tissue, including from executed prisoners or prisoners of conscience, consistent with recommendations by [Global Rights Compliance on Mitigating Human Rights Risks in Transplantation Medicine](https://globalrightscompliance.com/project/do-no-harm-policy-guidance-and-legal-advisory-report/). For all studies that use human organs or tissues authors must provide sufficient evidence that they were procured in line with [WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation](https://www.edqm.eu/documents/52006/286852/WHO+guiding+principles+on+human+cell%2C+tissue+and+organ+transplantation%2C+as+endorsed+by+the+63rd+WHA%2C+May+2010%2C+Resolution+WHA63.22.pdf/623474ce-1823-ea00-8462-51a144c6a791). The source of the organs or tissues used in clinical research must be transparent and traceable. Authors of manuscripts describing organ transplantation must additionally declare within the manuscript: - that autonomous consent free from coercion was obtained from the donor(s) or their next of kin; and - that organs/tissues were not sourced from executed prisoners or prisoners of conscience. All animal experiments should comply with the [ARRIVE guidelines](https://arriveguidelines.org/) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32010L0063), or the [National Research Council's Guide for the Care and Use of Laboratory Animals](https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Informed Consent and Patient Details

Studies on patients or volunteers (including organ/tissue donors) require informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author, but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. Unless the author has written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Institutional Review Board

Please download, and fill out the [Ethics and IRB worksheet](https://www.msacl.org/JMSACL_ETHICS_IRB.php), and include with your submission.

STARD Initiative

JSMACL supports the [STARD initiative](https://www.equator-network.org/reporting-guidelines/stard/#:~:text=The%20objective%20of%20the%20STARD,its%20generalisability%20(external%20validity) on reporting of diagnostic accuracy.

Race, Ethnicity and Racism

Race and ethnicity are sociopolitical constructs. Humans do not have biological races, at least based on modern biological criteria for the identification of geographical races or subspecies. Studies that use the constructs of race and/or ethnicity should explicitly motivate their use. Race/ethnicity should not be used as proxies for other variables – for example, socioeconomic status or income. For studies involving data collected from human participants, researchers should explain: - who provided the classification terms (the participants, the researchers or third parties); - what the classification terms are; - how racial/ethnic identity was determined (by the participants, the researchers or third parties). This information should be provided in the **Methods** section of your manuscript. Biomedical studies should not conflate genetic ancestry (a biological construct) and race/ethnicity (sociopolitical constructs): although race/ethnicity are important constructs for the study of disparities in health outcomes and health care, empirically established genetic ancestry is the appropriate construct for the study of the biological aetiology of diseases or differences in treatment response. If race/ethnicity are used in the context of disease etiology due to the unavailability of genetic ancestry data, this should be done with caution and clarification. Racism is scientifically unfounded and ethically untenable. Editors reserve the right to request modifications to (or correct or otherwise amend post-publication), and in severe cases refuse publication of (or retract post-publication), racist content. Editors use the guiding criteria I-IV set out in the section Research on human populations (see above) to identify content that potentially undermines the equal dignity and rights of humans of all races/ethnicities.

Sex, Gender (identity/presentation), and Sexual Orientation

Researchers are encouraged to follow the [‘Sex and Gender Equity in Research – SAGER – guidelines’](https://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6) and to include sex and gender considerations where relevant ([overview can be found here](https://www.ease.org.uk/wp-content/uploads/2016/09/Sager.for-web.pdf)). We recommend consulting the full guidelines when designing research studies and before submission. These guidelines apply to studies involving humans, vertebrate animals and cell lines. Authors should use the terms **sex** (biological attribute) and **gender** (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. >**Sex** generally refers to a set of biological attributes that are associated with physical and physiological features such as chromosomal genotype, hormonal levels, internal and external anatomy. A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth") and is in most cases based solely on the visible external anatomy of a newborn. In reality, sex categorizations include people who are intersex/have differences of sex development (DSD). >**Gender** generally refers to socially constructed roles, behaviors and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. The following recommendations and requirements (adapted from the SAGER guidelines) apply to studies under consideration at JMSACL involving human participants and vertebrate animals, where relevant to the topic of study. We also urge responsible communication of research findings on sex and gender differences so as to avoid inadvertent perpetuation of harmful gender stereotypes. - Title and/or abstract should indicate when the findings apply to only one sex or gender - describe whether sex and gender were considered in the study design, whether sex and/or gender of participants was determined based on self-report or assigned (and methodology used). - data should be reported disaggregated for sex and gender where this information has been collected and consent has been obtained for reporting and sharing individual-level data; disaggregated numbers for individual experiments must be provided in the source data as appropriate. - if sex- and gender-based analyses have been performed _a priori_, results should be reported regardless of positive or negative outcome. Authors should refrain from conducting post-hoc sex- and gender-based analysis if the study design is insufficient (for example, low sample size) to enable meaningful conclusions. - If no sex- and gender-based analyses have been performed, authors should justify reasons for lack of analysis. - Sex and gender-based analyses (SGBA) should be integrated into research design when research involves or pertains to humans, animals or eukaryotic cells. This should be done in accordance with any requirements set by funders or sponsors and best practices within a field. - Sex and/or gender dimensions of the research should be addressed within the article or declared as a limitation to the generalizability of the research. - Definitions of sex and/or gender applied should be explicitly stated to enhance the precision, rigor and reproducibility of the research and to avoid ambiguity or conflation of terms and the constructs to which they refer.

Studies Involving Vulnerable Groups

For manuscripts reporting studies involving vulnerable groups where there is the potential for coercion or where consent may not have been fully informed, extra care will be taken by the editor. The manuscript may be referred to an internal editorial oversight group for further scrutiny. Consent must be obtained for all forms of personally identifiable data including biomedical, clinical, and biometric data. Documentary evidence of consent must be supplied if requested.

Human Biospecimens

For describing human biospecimens, we recommend referring to the BRISQ reporting guidelines (Biospecimen Reporting for Improved Study Quality) and ensuring at least Tier 1 characteristics are provided ([doi: 10.1002/cncy.20147](https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.20147)).

Human Transplantation Studies

Authors must also include a statement in their manuscript attesting that no organs/tissues were procured from prisoners and providing details of the institution(s)/clinic(s)/department(s) via which organs/tissues were procured while taking care to not violate privacy of donors. For retrospective transplantation studies, authors must include a testament confirming that informed consent was obtained from all participants or that the need for informed consent was waived by the ethics committee/institutional review board.

Reporting Standards and Availability of Data, Materials, Code and Protocols

An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in JMSACL is that authors are required to make materials, data, code, and associated protocols promptly available to readers without undue qualifications. Any restrictions on the availability of materials or information must be disclosed to the editors at the time of submission. Any restrictions must also be disclosed in the submitted manuscript. After publication, readers who encounter refusal by the authors to comply with these policies should contact the chief editor of the journal. In cases where editors are unable to resolve a complaint, the journal may refer the matter to the authors' funding institution and/or publish a formal statement of correction, attached online to the publication, stating that readers have been unable to obtain necessary materials to replicate the findings.

Article Types

There are a number of article types currently available for publication in JMSACL. Descriptions of each Article Type follow. Word count specifications do not include the abstract, references, table and figure legends or supplemental material. - Original Research - Short Report - Review - Mini-Review - Case Report - Inspirational Profile - Editorial

Original Research

Intended for presentation of original research. The information presented must be sufficiently detailed as to enable readers to both understand the material and permit replication of the work. > **Original Research Specifications** - Abstract: Yes ([structured](https://www.nlm.nih.gov/bsd/policy/structured_abstracts.html)); < 251 words - Length: ~2,000-5,000 words recommended - References: No limit - Authors: No limit - Tables &or Figures: No limit - Supplemental Data: Permitted

Short Report

Intended for brief or short communications. A shorter format for presenting original research, such as single findings with no more than ??three?? (total) figures and tables. Also acceptable for reporting technical improvements of previously published procedures, replication of previous research, or Practical Training concepts. > **Short Report Specifications** - Abstract: Yes ([structured](https://www.nlm.nih.gov/bsd/policy/structured_abstracts.html) for original research, or free-form for other); < 251 words - Length: <~2,500 words - References: No limit - Authors: No limit - Tables &or Figures: 3 (total) - Supplemental Data: ??Not Permitted??

Review

Reviews are intended to provideo comprehensive coverage of a topic, including potential future directions. > **Review Specifications** - Abstract: Yes (free form); < 251 words - Length: ~ 2,500 - 6,000 words. - References: No limit - Authors: No limit - Tables &or Figures: No limit - Supplemental Data: Permitted

Mini-Review

Mini-Reviews are intended to provide a high-level overview of a topic, including potential future directions. > **Mini-Review Specifications** - Abstract: Yes (free form); < 251 words - Length: ~ 1,000 - 2,500 words. - References: No limit - Authors: No limit - Tables &or Figures: No limit - Supplemental Data: Permitted > **Mini-Review Examples** > - Tandem mass spectrometry in the clinical laboratory: A tutorial overview > - The importance of clinical tissue imaging

Case Study

Case Studies are intended to examine an interesting or unusual situation with the goal of educating the reader. Include a case description followed by the case discussion and resolution. The author should list up to 5 points of interest at the end of the manuscript. > **Case Report Specifications** - Abstract: No - Length: < 1500 words. - References: No limit - Authors: No limit - Tables &or Figures: <5 - Supplemental Data: Not permitted

Inspirational Profile

Inspirational Profiles are generally invited submissions made to distinguished clinical scientists who have used advanced technology to advance the field of clinical analysis. These profiles allow them to candidly share their paths to success, personal and professional, as well as their philosophical views. > **Inspirational Profile Specifications** - Abstract: Yes (free-form); < 251 words - Length: No limit - References: No limit - Authors: No limit - Tables&or Figures: No limit. - Supplemental Data: Not permitted

Editorial

Editorials provide opinions and observations by an expert in the field about: (i) the subject matter or content of a scientific paper published in any journal, (2) an observation of the field, or (3) an expression by an expert of their judgment, guidance or advice. > **Editorial Specifications** - Abstract: No - Length: < 1500 words. - References: No limit - Authors: <5 - Tables &or Figures: Not permitted - Supplemental Data: Not permitted

Templates

Please use the [Word template that can be downloaded here](JMSACL_template.docx).

Document Format

Please format your submission documents according to the guidance below. - Format as a WORD document (.doc or .docx). - Do NOT format as LaTeX or PDF. It makes it difficult to copyedit. - Number all **pages** continuously. - Number all **lines** continuously (do not restart on new page). - Font: Calibri (preferred) - Font Size: 11 or 12 pt - Line Spacing:1.5 or 2.0 - Single-column

Content Format

Article Sections

• Divide your article into clearly defined and numbered sections. Number subsections 1.1 (then 1.1.1, 1.1.2, ... up to 5 levels), then 1.2, etc.
• Use the numbering format when cross-referencing within your article. Do not just refer to "the text."
• You may give subsections a brief heading. Headings should appear on a separate line.
• Do not include the article abstract within section numbering.

Footnotes

Use footnotes sparingly. If you include footnotes in your article, ensure that they are numbered consecutively. You may use system features that automatically build footnotes into text. Alternatively, you can indicate the position of footnotes within the text and present them in a separate section at the end of your article.

Nomenclature and Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. Italicize gene symbols and use the approved gene nomenclature where it is available. For human genes, please refer to the HUGO Gene Nomenclature Committee (HGNC). Protein products are not italicized.

Citing the Supplier for an Item in Materials & Methods

When listing materials in the Materials and Methods section it is also necessary to include the supplier's name. You can either: (i) describe where the item was obtained and then include the location in parenthesis, or (ii) list the supplier and location in parentheses after the item's name. For example (i): > Formic acid was obtained from Sigma-Aldrich (St. Louis, MO). For example (ii): > Formic acid (Sigma-Aldrich, St. Louis, MO) was used.

Figures

Please observe the following guidelines for figures and graphs. Standardize the format for multiple graphs used in a document. **Within the Document**

• Do not abbreviate the term "Figure(s)".
• Capitalize the term "Figure(s)".
• Parenthetically embrace Figure with round brackets ... (Figure 1). Do NOT use square brackets [ ].
• Embed Figures in the manuscript file
  • Although figures larger than 10 MB should be provided in separate source files.
• Include Captions with your Figure(s).
• Captions must be editable (no images).

**Within the Figure**

• Use a sans-serif font (Arial, Helvetica, Calibri are preferred).
• A 10 pt font size is recommended but can range from 8 pt to 12 pt.
• Avoid using colored type.
• Simple solid or open symbols reduce well.
• Label graphs on the ordinate and abscissa with the parameter or variable being measured, the units of measure in parentheses, and the scale. Scales with large or small numbers should be presented as powers of 10.
• Avoid the use of light lines. Instead, use black-and-white, hatched, and cross-hatched designs for emphasis.
• Capitalize only the first letter in a label, not every word (however, proper nouns should always be capitalized).
• Units should be included in parentheses. Use SI notation. If there is room, write out variables – e.g., Pressure (MPa), Temperature (K). Seconds should be abbreviated as “s”, not “sec”; minutes should be abbreviated as “min.”; and hours should not be abbreviated.
• Variables are always set in italics or as plain Greek letters (e.g., P, T, µ). The rest of the text in the figure should be plain or bold text.
• In a color figure, type atop a color region should be in bold face.
• When figures are assembled from multiple gels or micrographs, a line or space should indicate the border between two original images.
• Use leading zeros on all decimals – e.g., 0.3, 0.55 – and report only significant digits.
• Use capital letters for part labels in multipart figures – A, B, C, etc. These should be 10 pt and bold in the final figure. When possible, place part labels in the upper left corner of each figure part; if a part is an image, set labels inside the perimeter so as not to waste space.
• Avoid subpart labels within a figure part. Instead, maintain the established sequence of part labels [e.g., use A, B, C, D, E instead of A, B, C(a), C(b), C(c)]. If use of subpart labels is unavoidable, use lowercase letters (a, b, c), prime symbols, or lowercase Roman numerals (i, ii, iii). Use numbers (1, 2, 3) only to represent a time sequence of images.
• When reproducing images that include labels with illegible computer-generated type (e.g., units for scale bars), omit such labels and present the information in the caption instead.
• Sequences may be reduced considerably, so the typeface in the original should be clear. There should be about 130 characters and spaces per line for a sequence occupying the full width of the printed page and about 84 characters and spaces per line for a sequence occupying two columns.

Tables

**Within the Document**

• Do not abbreviate the term "Table(s)".
• Capitalize the term "Table(s)".
• Embed Figures in the manuscript file
• Include Captions with your Table(s).
• Captions must be editable (no images).

**Within the Table** [View Comprehensive Table Submission Formating Guidelines Here](https://help.scholasticahq.com/article/193-table-submission-guidelines-for-typesetting-customers)

Images

Acceptable file types include EPS, PDF, TIFF or JPG (not optimized for web). Please DO NOT supply files that are optimized for screen or web use (e.g., GIF, BMP, PICT, WPG); the resolution is too low. Use a minimum of 300 dpi. For color or grayscale photographs (halftones): always use a minimum of 300 dpi. For bitmapped line drawings use a minimum of 1000 dpi. For combinations of bitmapped line/half-tone (color or grayscale) a minimum of 500 dpi is required. Please embed your artwork, in context, within the body of your manuscript and also include a separate file for each image. Within EPS files please be sure to outline the text. Within PDFs, if the text was not previously outlined in an AI or EPS file, please be sure to embed the fonts used.

Color Artwork Accessibility

Please ensure that color images are accessible to all, including those with impaired color vision. Learn more about color and web accessibility - [Web Accessibility Guidelines for Contrast and Color](http://web-accessibility.carnegiemuseums.org/design/color/) - [Web Accessibility in Mind (WebAIM)](https://webaim.org/resources/contrastchecker/).

Math Formulae

- Submit math equations as editable text and not as images. - Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. - In principle, variables are to be presented in italics. - Powers of e are often more conveniently denoted by exp. - Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Content Order

For Original Research Articles and Short Reports

- Title Page - Title - Author Information - Ensure that ONE (1) author has been designated as the corresponding author with following contact details: - E-mail address - Full postal address - Phone number - Keywords - Abbreviations - Abstract - Introduction - Materials and Methods - Results and Discussion (combined or separate) - Conclusions - Acknowledgements (optional) - CRediT Author Statement - Conflicts of Interest - Data Sharing Statement - Ethics Statement - Funding Support - Funding Influence - Supplementary Material (optional) - References

For Other Article Types

Other Article Types may adopt a more flexible construct, but should include - Title Page - Title - Author Information - Ensure that one author has been designated as the corresponding author with contact details: - E-mail address - Full postal address - Phone number - Keywords - Abbreviations - CRediT Author Statement - Conflicts of Interest - Ethics Statement - Funding Support - Funding Influence - References (optional) If your article includes any Videos or other Supplementary material, this should be included in your initial submission for peer review purposes.

Content Detail

Title page

Please include the following details on the title page: **Article Title.** Should be concise and informative and, where possible, a statement of the conclusion presented in the manuscript. Avoid abbreviations and formulae unless they are established and widely understood (see Standard Abbreviations).

• For Corrigenda and Editorials, the title of your manuscript should have the following format:
  • 'Corrigendum: Title of Original Article'
  • 'Editorial: Title of Research Topic'

- Any running title should be a maximum of five (5) words in length. **Author Names.** Provide the given (first) name and family (last) name of each author. The order should match the order in the submission system.

• _Equally Contributing Authors_ should be marked with a †. Please use the appropriate statement(s) to indicate equal contribution:
  • For _Equal Contribution_ USE 'These authors contributed equally to this work.'
  • For _Shared First Authorship_ USE 'These authors share first authorship.'
  • For _Shared Senior Authorship_ USE 'These authors share senior authorship.'
  • For _Shared Last Authorship_ USE 'These authors share last authorship.'
  • For _Equal Contribution and First Authorship_ USE 'These authors contributed equally to this work and share first authorship.'
  • For _Equal Contribution and Senior Authorship_ USE 'These authors contributed equally to this work and share senior authorship.'
  • For _Equal Contribution and Last Authorship_ USE 'These authors contributed equally to this work and share last authorship.'

• _Consortium/Group Authorship_ should be listed in the manuscript with the other author(s). In cases where authorship is retained by the consortium/group, the consortium/group should be listed as an author separated by a comma or 'and'. The consortium/group name will appear in the author list, in the citation, and in the copyright. If provided, the consortium/group members will be listed in a separate section at the end of the article. For the collaborators of the consortium/group to be indexed in PubMed, they do not have to be inserted in the JMSACL submission system individually. However, in the manuscript itself, provide a section with the name of the consortium/group as the heading followed by the list of collaborators, so they can be tagged accordingly and indexed properly. Example: John Smith, Barbara Smith and The Collaborative Working Group. In cases where work is presented by the author(s) on behalf of a consortium/group, it should be included in the author list separated with the wording 'for' or 'on behalf of.' The consortium/group will not retain authorship and will only appear in the author list.

**Affiliations.** Add affiliation addresses, referring to WHERE the work was carried out (not the current affiliation or location), below the author names. Indicate affiliations using a superscript lower-case **letter** immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the email address of each author. **Corresponding Author.** The corresponding author(s) should be marked with an asterisk (\*) in the author list and their name and contact email address placed below the Affiliations list. Example: ```*Corresponding Author: Denise Maximus (dmax@iupscience.edu)``` The corresponding author is responsible for handling correspondence for the article at all stages of the review and publication process, as well as post-publication. **Present/permanent Address.** If an author has moved since the work described in the article was carried out, or the author was visiting during that time, a "present address" (or "permanent address") can be indicated by a footnote to the author's name. The address where the author carried out the work must be retained as their main affiliation address. Use superscript Arabic **numerals** (e.g., 1,2,3) for such footnotes. **Keywords.** Provide 5 to 7 keywords for indexing purposes. Keywords should be written in English. Avoid keywords consisting of multiple words (using "and" or "of"). Only use abbreviations in keywords if they are firmly established in the field. **Abbreviations.** Include a list of non-standard abbreviations after the keywords and before the abstract. > Example: MTB, _Mycobacterium tuberculosis_; TLC, thin layer chromatography; HPLC, high pressure liquid chromatography. Abbreviations should be avoided unless the word they represents appears multiple times. They must be defined upon first use in the abstract and then again in the main text.

Executive Overview and Importance

When you submit your manuscript, you will be required to summarize in 400 characters (including spaces) an Executive Overview that should be writtern avoiding any technical language or non-standard acronyms. The aim should be to convey the meaning and importance of this research to a **non-expert**.

Abstract

Depending on the Article Type you are submitting, you may be required to provide an abstract. Your abstract should be concise and not exceed 250 words. [Structured Abstracts](https://www.nlm.nih.gov/bsd/policy/structured_abstracts.html) are requried for **Original Research** and **Short Reports**. Other article types do not require a structured abstract, unless the author thinks it appropriate. Some guidelines: - Abstracts must be able to stand alone, as abstracts are often presented separately from the article. - Avoid references. - Avoid non-standard abbreviations. If any are essential to include, ensure they are defined within your abstract at first mention.

Graphical Abstract

>??**Place for this on Scholastica???** You are encouraged to provide a graphical abstract at submission. The graphical abstract should summarize the contents of your article in a concise, pictorial form which is designed to capture the attention of a wide readership. A graphical abstract will help draw more attention to your article and support readers in digesting your research. Some guidelines: - Submit your graphical abstract as a separate file in the online submission system. - Ensure the image is a minimum of 531 x 1328 pixels (h x w) or proportionally more and is readable at a size of 5 x 13 cm using a regular screen resolution of 96 dpi. - Preferred file types for graphical abstracts are TIFF, EPS, PDF or MS Office files.

Sections (Numbered)

The following sections should not be numbered. The manuscript should be organized by headings and subheadings. You may insert up to 5 heading levels into your manuscript (i.e.,: 3.2.2.1.2 Heading Title). For Original Research articles, it is recommended to organize your manuscript in the following sections or their equivalents.

Introduction

Succinct, no subheadings.

Materials and Methods

This section may be divided by subheadings and should contain sufficient detail so that when read in conjunction with cited references, all procedures can be repeated. For experiments reporting results on animal or human subject research, an ethics approval statement should be included in this section (for further information, see the 'Bioethics' section of our polices and publication ethics.)

Results

This section may be divided by subheadings. Results should provide details on the outcome of your experiements.

Discussion

May alternatively be named "Conclusions". This section may be divided by subheadings. This section should:

• cover the key findings of the study,
• discuss any prior research related to the subject to place the novelty of the discovery in the appropriate context,
• discuss the potential shortcomings and limitations on their interpretations,
• discuss their integration into the current understanding of the problem and how this advances the current views,
• speculate on the future direction of the research, and
• freely postulate theories that could be tested in the future.

Sections (Non-Numbered)

The following sections should not be numbered.

Acknowledgements

Acknowledgements should be placed in a section entitle **Acknowledgements** that should appear immediately following the Conclusion of the manuscript and prior to the References. Acknowledgements should be brief, and should not include thanks to anonymous referees or editors, inessential words, or effusive comments. Acknowledgements can be used to thank specific colleagues, institutions, or agencies that aided the efforts of the authors publishing the work, but do not qualify for authorship . It should NOT be used to list contributors who meet the criteria for authorship. We urge authors to carefully consider researcher contributions and authorship criteria when involved in multi-region collaborations involving local researchers so as to promote greater equity in research collaborations. Should the content of the manuscript have previously appeared online, such as in a thesis or preprint, this should be mentioned here, in addition to listing the source within the reference list. Acknowledgements should not be used to declare competing interests or funding sources. These should be declared separately in the **Conflicts of Interest** and **Funding Sources** sections, respectively.

Conflicts of Interest

>The [Conflicts of Interest Worksheet](https://www.msacl.org/JMSACL_COI.php) must be completed and included with your submission. >?? Note: Do NOT convert the .doc/.docx template to another file type. >Authors with no competing interests to declare should select the option, "I have nothing to declare". >Author signatures are not required. >If there are no interests to declare, please choose the first option in the template. In the interests of transparency and to help readers form their own judgements of potential bias, JMSACL requires authors to declare any competing financial and/or non-financial interests in relation to the work described. The corresponding author is responsible for submitting a competing interests' statement on behalf of all authors of the paper. Competing Interests are defined as financial and non-financial interests that could directly undermine, or be perceived to undermine the objectivity, integrity and value of a publication, through a potential influence on the judgements and actions of authors with regard to objective data presentation, analysis and interpretation. Financial competing interests include any of the following: - Funding: Research support (including salaries, equipment, supplies, and other expenses) by organizations that may gain or lose financially through this publication. A specific role for the funder in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript, should be disclosed. - Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication. - Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration (including reimbursements for attending symposia) from organizations that may gain or lose financially; patents or patent applications (awarded or pending) filed by the authors or their institutions whose value may be affected by publication. For patents and patent applications, disclosure of the following information is requested: patent applicant (whether author or institution), name of inventor(s), application number, status of application, specific aspect of manuscript covered in patent application. - There is no threshold limit. ?? - Diversified mutual funds or investment trusts to do not constitute a competing financial interest. - Non-financial competing interests: Non-financial competing interests include personal or professional relations with organizations and individuals. We encourage authors and referees to declare any unpaid roles or relationships that might have a bearing on the publication process. Examples of non-financial competing interests include (but are not limited to): - Unpaid membership in a government or non-governmental organization - Unpaid membership in an advocacy or lobbying organization - Unpaid advisory position in a commercial organization - Writing or consulting for an educational company - Acting as an expert witness All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include: - Employment - Consultancies - Stock ownership - Honoraria - Paid expert testimony - Patent applications or registrations - Grants or any other funding

CRediT Author Statement

Corresponding authors are required to acknowledge co-author contributions using CRediT (Contributor Roles Taxonomy) roles: - **Conceptualization** - _Ideas; formulation or evolution of overarching research goals and aims._ - **Data curation** - _Management activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later re-use._ - **Formal analysis** - _Application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data._ - **Funding acquisition** - _Acquisition of the financial support for the project leading to this publication._ - **Investigation** - _Conducting a research and investigation process, specifically performing the experiments, or data/evidence collection._ - **Methodology** - _Development or design of methodology; creation of models._ - **Project administration** - _Management and coordination responsibility for the research activity planning and execution._ - **Resources** - _Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools._ - **Software** - _Programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components._ - **Supervision** - _Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team._ - **Validation** - _Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs._ - **Visualization** - _Preparation, creation and/or presentation of the published work, specifically visualization/data presentation._ - **Writing – original draft** - _Preparation, creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation)._ - **Writing – review and editing** - _Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary, or revision – including pre or post-publication stages._ Not all CRediT roles will apply to every manuscript and some authors may contribute through multiple roles. >**EXAMPLE : CRediT Author Statement** Author Contributions: Conceptualization, PLL and JS; Methodology, ZHJ. and SHJ; Software, HS; Validation, SFC and CYC; Investigation, DCW; Resources, SPT and PLL; Data Curation, HS and SHJ; Writing—original draft preparation, HS; Writing—review and editing, JS and HS; Visualization, HS; Supervision, JS and PLL; Project Administration, DCW. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

All published manuscripts reporting original research in JMSACL must include a data availability statement. The data availability statement must make the conditions of access to the “minimum dataset” (necessary to interpret, verify and extend the research in the article) transparent to readers. This minimum dataset may be provided through deposition in public community/discipline-specific repositories, custom proprietary repositories for certain types of datasets, or general repositories like Figshare, Zenodo and Dryad. Providing large datasets in supplementary information is strongly discouraged and the preferred approach is to make data available in repositories. *Scientific Data* maintains a [list of approved and recommended data repositories](https://www.nature.com/sdata/policies/repositories) to support researchers seeking suitable repositories for their data. Authors are responsible for obtaining all necessary permissions and ensuring compliance with local regulatory requirements for data sharing. Ensuring that data is available may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you can state the reason why (e.g., your research data includes sensitive or confidential information such as patient data) as part of the Data Availability statement. This statement will appear with your published article. **Data availability statements should include information where relevant on the following aspects:** - Information about access to primary datasets (generated during the study) and referenced datasets (datasets analyzed in the study) must be provided. Where data are publicly available, accession codes or other unique identifiers if relevant must be provided. - **Clinical trial data**: data availability statements for manuscripts reporting clinical trial data should follow the standards set out in the ICMJE recommendations on clinical trial data sharing and provide the following information: - whether individual de-identified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer); - what data in particular will be shared; - whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); - when the data will become available and for how long; - by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).

Data Availability Subject to Controlled Access

In such cases, the Data Availability statement should include the following information: - reasons for controlled access (eg., privacy, ethical/legal issues), - conditions of access must be described precisely including contact details for access requests, - timeframe for response to requests, - restrictions imposed on data use via data use agreements. A copy or link to the data use agreement should be provided if requested by editors. Restrictions on controlled access datasets including restrictions on downstream data reuse or authorship requirements must be clearly described in manuscript and to editors at the time of submission. Editors may decline further consideration of the manuscript after evaluation if restrictions are found to be unduly prohibitive.

Third Party Data

When data obtained from third parties cannot be made available, the restrictions should be clearly stated in the Data Availability statement. Authors must make data available for purposes of peer review, if requested by reviewers, within the terms of a data use agreement and if compliant with ethical and legal requirements. Researchers should provide information in the manuscript on their data collection methods sufficient to support peer review. If data processing steps were performed by the third-party, out of the control of the authors, this should be clearly stated in the Methods. Editors reserve the right to decline consideration if a manuscript fails to provide sufficient information regarding data collection approach.

Data Citation

Datasets that have been deposited in repositories should be included as formal citations in the article reference list. This includes datasets generated during the study as well as existing datasets analyzed during the study. Citations of datasets should include the minimum information recommended by DataCite and include: author(s), title, publisher (repository name), and identifier. Dataset identifiers including DOIs should be expressed as full URLs. For example: Hao, Z., AghaKouchak, A., Nakhjiri, N. & Farahmand, A. Global Integrated Drought Monitoring and Prediction System (GIDMaPS) Data sets. figshare http://dx.doi.org/10.6084/m9.figshare.853801 (2014)

Ethics Statement

Based on guidance from the [Ethics and IRB Worksheet](https://www.msacl.org/JMSACL_ETHICS_IRB.php) authors must summarize their IRB approval and whether they collected informed consent

Funding Sources

Authors must disclose any funding sources who provided financial support for the conduct of the research and/or preparation of the article. When acknowledging funding, recommended best practice is that authors should acknowledge funders and grants when the activities that contributed to that publication: - were within scope of the acknowledged grant and - arose directly from a specific grant List funding sources in this standard way to facilitate compliance with funder's requirements: > _Funding Support: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa]._ It is not necessary to include detailed descriptions on the program or type of grants, scholarships and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, include the name of the institute or organization that provided the funding. An appropriate format for grant funding is: > _ABC discloses support for the research of this work from Funder \[grant number xxxx\], Funder \[grant number xxxx\] and Funder \[grant number xxxx\]. DEF discloses support for publication of this work from Funder \[grant number xxxx\] and Funder \[grant number xxxx\]. If **NO** funding has been provided for the research, it is recommended to include the following sentence: > _Funding Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors._

Funding Influence

The role of funding sources, if any, should be declared in relation to the study design, collection, analysis and interpretation of data, writing of the report and decision to submit the article for publication. _If funding sources had no involvement, then such should be stated in this section._

Supplementary Materials

Please label and reference your Supplemental Figures and/or Tables using an "S" before the number. For example: Table S1, Table S2 or Figure S4, Figure S5. Supplementary Material provide the reader with information that supports your study without breaking up the narrative or distracting from the main purpose of your paper. Supplementary files do not receive a separate DOI. > Supplementary Material will NOT be formatted or typeset by the production team, so please ensure that all information is clearly presented without tracked changes/highlighted text/line numbers, and the appropriate caption is included in the file. > To avoid discrepancies between the published article and the supplementary material, please do not add the title, author list, affiliations or correspondence in the supplementary files. > You must use the template document for your Supplementary Material. Supplementary Material includes content that can help readers understand your research more fully. If you have copious amounts of raw data or information that is difficult to present in textual form, consider uploading it to an online site. This supports a growing movement to make data more freely available for re-analysis. If you do create an online portal to your data, note it prominently in your paper with the correct URL and access procedures if it is a secured site, or if needed, with clear directions on how to contact the author to obtain access.

Guidelines

- Each Supplemental Material FILE should have a short caption which will be placed at the bottom of the article, where it can assist the reader and also be used by search engines. - Any tables and figures included Supplementary Materials should be numbered as a separate sequence from the main paper. - Supplementary Materials should not be a dumping ground for information. Do not include vague or irrelevant information. - Cite all Supplementary instances (e.g., Data, Figures, Tables) in the main manuscript text. - Data Sharing : We recommend you upload research data to a suitable specialist or generalist repository and reference it in the Supplementary Materials, or in the main manuscript. - Be aware that the Supplementary Material file provided will appear online in the exact same file type as received. - !! Do not make annotations or corrections to a previous version of a supplementary file. Provide updated files if at any stage of the publication process you wish to make changes to submitted Supplementary Materials. - Switch off the option to track changes in Microsoft Office files. If tracked changes are left on, they will appear in your published version. Supplementary material can be uploaded as:

• data sheet (Word, Excel, CSV, CDX, FASTA, PDF or Zip files)
• presentation (PowerPoint, PDF or Zip files)
• image (CDX, EPS, JPEG, PDF, PNG or TIF/TIFF),
• table (Word, Excel, CSV or PDF)
• audio (MP3, WAV or WMA)
• video (AVI, DIVX, FLV, MOV, MP4, MPEG, MPG or WMV)

Technical requirements for supplementary images:

• 300 DPIs
• RGB color mode

References

Any references cited within your article should also be present in your reference list and vice versa. Some guidelines: - It is recommended that you do not include unpublished results and personal communications in your reference list, though you may mention them in the text of your article. - Any unpublished results and personal communications included in your reference list must follow the standard reference style of the journal. In substitution of the publication date add "unpublished results" or "personal communication." - References cited as "in press" imply that the item has been accepted for publication. - Within the Reference section you need to list all authors in the reference up to 20. Always include the last author. [More info](https://libguides.jcu.edu.au/apa/authors). - Given names of authors should be abbreviated to initials (e.g., Smith, J., Lewis, C.S., etc.) - Personal communications should be documented by a letter of permission - Any inclusion of verbatim text must be contained in quotation marks and clearly reference the original source

Reference Links

In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. We encourage the use of Digital Object Identifiers (DOIs) as reference links as they provide a permanent link to the electronic article referenced. Please note the format of such citations should be in the same style as all other references in the paper.

Reference Style

Indicate references by adding a number within square brackets in the text. You can refer to author names within your text, but you must always give the reference number, e.g., "as demonstrated \[3,6]. Barnaby and Jones \[8] obtained a different result ...". Number references in the order they appear in your article.

Reference Examples

### Reference to a Journal Publication with No DOI: > Sondheimer N, Lindquist S. Rnq1: An epigenetic modifier of protein function in yeast. Mol Cell (2000) 5:163-72. ### Reference to a Journal Publication: > J. van der Geer, T. Handgraaf, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2020) 51 – 59. https://doi.org/10.1016/j.sc.2020.00372. ### Reference to a Journal Publication with an Article Number: > J. van der Geer, T. Handgraaf, R.A. Lupton, 2022. The art of writing a scientific article. Heliyon. 19, e00205. https://doi.org/10.1016/j.heliyon.2022.e00205. ### Reference to an Article that has Not Yet been Issued an Article Number: > VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. ### Reference to a Preprint > Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided. > EXAMPLE: CD73 restrains mutant ß-catenin oncogenic activity in endometrial carcinomas. Rebecca M Hirsch, Sunthoshini Premsankar, Katherine C Kurnit, Lilly F Chiou, Emily M Rabjohns, Hannah N Lee, Russell R Broaddus, Cyrus Vaziri, Jessica L Bowser. bioRxiv. https://doi.org/10.1101/2024.11.18.624183 ### References in a Special Issue > Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue. ### Reference to a Book: > W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000. ### Reference to a Chapter in a Book: > G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2020, pp. 281 - 304. ### Reference to a Website: > Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/, 2023 (accessed 13 March 2023). > At a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list. ### Reference to a Dataset: > When citing data references, you should include: > > - author name(s) > - dataset title > - data repository > - version (where available) > - year > - global persistent identifier > ???? YES/ NO???? Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article. ????? > \[dataset\] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions , Mendeley Data, v1, 2015. https://doi.org/10.1234/abc12nb39r.1. ### Reference to Software: > \[software\] E. Coon, M. Berndt, A. Jan, D. Svyatsky, A. Atchley, E. Kikinzon, D. Harp, G. Manzini, E. Shelef, K. Lipnikov, R. Garimella, C. Xu, D. Moulton, S. Karra, S. Painter, E. Jafarov, S. Molins, Advanced Terrestrial Simulator (ATS) v0.88, Zenodo, March 25, 2020. https://doi.org/10.1234/zenodo.3727209. ### Web References > When listing web references, as a minimum you should provide the full URL and the date when the reference was last accessed. Additional information (e.g. DOI, author names, dates or reference to a source publication) should also be provided, if known. > You can list web references separately under a new heading directly after your reference list or include them in your reference list.

After Acceptance

Proof Correction

**Need to see how proof correction works on Scholastica and the update accordingly** To ensure a rapid publication process we ask you to provide proof corrections within two days. Corresponding authors will be sent an email which includes a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to Word. You can edit text, comment on figures and tables and answer questions raised by our copy editor. Our web-based proofing service ensures a faster and less error-prone process. You can choose to annotate and upload your edits on the PDF version of your article, if preferred. We will provide you with proofing instructions and available alternative proofing methods in our email. The purpose of the proof is to check the typesetting, editing, completeness and correctness of your article text, tables and figures. Significant changes to your article at the proofing stage will only be considered with approval of the journal editor.

Tier System

JMSCL has a triple-tiered dues structure following the UN model for A, B, and C countries, based on the World Bank's indicators of Gross National Income. - Residents of Tier A countries pay 100% - Residents of Tier B countries pay 30% - Residents of Tier C countries pay 15% Your tier is determined by the country you currently live (not your country of origin)

Country Tier Chart

Find the country in which you currently reside to determine what tier you qualify for. | Tier A | Tier B | Tier C | | --- | --- | --- | | Andorra

Antigua and Barbuda

Aruba

Australia

Austria

Bahamas

Bahrain

Barbados

Belgium

Bermuda

British Virgin Islands

Canada

Cayman Islands

Channel Islands

Chile

Croatia

Cyprus

Czech Republic

Denmark

Estonia

Faroe Islands

Finland

France

French Polynesia

Germany

Greece

Greenland

Guam

Hong Kong

Hungary

Iceland

Ireland

Isle of Man

Israel

Italy

Japan

Korea, Rep. of

Kuwait

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Monaco

Nauru

Netherlands

New Caledonia

New Zealand

Northern Mariana Islands

Norway

Oman

Poland

Portugal

Puerto Rico

Qatar

San Marino

Saudi Arabia

Seychelles

Singapore

Sint Maarten (Dutch part)

Slovak Republic

Slovenia

Spain

St. Kitts and Nevis

St. Martin (French part)

Sweden

Switzerland

Taiwan

Trinidad and Tobago

Turks and Caicos Islands

United Arab Emirates

United Kingdom

United States

Uruguay

Virgin Islands (U.S.)
















|Albania

Algeria

American Samoa

Angola

Argentina

Azerbaijan

Belarus

Belize

Bosnia and Herzegovina

Botswana

Brazil

Bulgaria

China

Colombia

Costa Rica

Cuba

Dominica

Dominican Republic

Ecuador

Equatorial Guinea

Fiji

Gabon

Georgia

Grenada

Guyana

Iran, Islamic Rep.

Iraq

Jamaica

Jordan

Kazakhstan

Lebanon

Libya

Macedonia, FYR

Malaysia

Maldives

Marshall Islands

Mauritius

Mexico

Montenegro

Namibia

Palau

Panama

Paraguay

Peru

Romania

Russian Federation

Serbia

South Africa

St. Lucia

St. Vincent and the Grenadines

Suriname

Thailand

Turkey

Turkmenistan

Tuvalu

Venezuela






















































|Afghanistan

Armenia

Bangladesh

Benin

Bhutan

Bolivia

Burkina Faso

Burundi

Cabo Verde

Cambodia

Cameroon

Central African Rep.

Chad

Comoros

Congo, Dem. Rep.of

Congo, Rep.of

Cote d'Ivoire

Djibouti

Egypt

El Salvador

Eritrea

Ethiopia

Gambia

Ghana

Guatemala

Guinea

Guinea-Bisseau

Haiti

Honduras

India

Indonesia

Kenya

Kiribati

Korea, Dem. Rep.

Kosovo

Kyrgyz Republic

Lao PDR

Lesotho

Liberia

Madagascar

Malawi

Mali

Mauritania

Micronesia Fed.

Moldova

Mongolia

Morocco

Mozambique

Myanmar

Nepal

Nicaragua

Niger

Nigeria

Pakistan

Papua New Guinea

Philippines

Rwanda

Samoa

Sao Tome and Principe

Senegal

Sierra Leone

Solomon Islands

Somalia

South Sudan

Sri Lanka

Sudan

Swaziland

Syrian Arab Republic

Tajikistan

Tanzania

Timor - Leste

Togo

Tonga

Tunisia

Uganda

Ukraine

Uzbekistan

Vanuatu

Vietnam

West Bank and Gaza

Yemen, Rep.

Zambia

Zimbabwe |

Fundamental Style and Grammatical Guidance

Numbers

• Use numerals with units of time or measure (6 min, 5 g, 273 K).
• Use numerals for numbers greater than nine (10 samples).
• Use words for numbers less than 10 (nine samples), except for units of time or measure (9 min).

>**Units of Measure** > >Measure is a general term that implies units of: >

• >
• volume (mL, cm3) >
• width or length (m,cm) >
• mass (g, mg) >
• temperature (°C, K) >
• concentration (g/mL, M) >

_Some exceptions:_

• Use all numerals in a series or range of values containing the number 10 or greater (e.g., 5, 8, and 12 samples).
• Use words for numbers that start with a sentence, unless that number is part of chemical name (e.g., "Nineteen samples were analyzed." "2-Butene was added.").

Spacing

• There is always a space between the number and the unit.
  • 2 mL, 0.6 cm, 3.2 ft, 0.015 mg, 8 K, 180 °C

• Exceptions
  • there is no space between the number and the percent-sign (%)
    • 85%
  • when using >, < and ±, include spaces between the numbers and sympbols if there are numbers on both sides of the symbol. Also include spaces if the symbol falls in between a variable and a number:
    • <25mL (no space)
    • 80 ± 9% (spaces)
    • p < 0.05 (spaces)

Use of "i.e." versus "e.g."

The difference between "i.e." and "e.g." is that "i.e." means "that is" and "e.g." means "for example": **"i.e."** is used to clarify or rephrase a statement to make it more precise or specific. >Example : The specific fruit eaten by Eve (i.e, an apple) was not as ripe as she had hoped. **"e.g."** is used to provide specific examples that fall under a more general category. > Example: The banquet table was over-flowing with various fruits (e.g., apples, bananas) for the guests. "i.e." and "e.g." are both Latin abbreviations, with "i.e." standing for _id est_ and "e.g." standing for _exempli gratia_. They are **not interchangeable** and should be used correctly to ensure the meaning of a sentence is retained. Use as (e.g., ...) and (i.e., ...).

Use of "respectively"

**"Respectively"** is used to map one serial list to another in the order specified. >The speeds of the car, motorcyle and bicycle were 62, 78 and 15 mph, respectively. This means that the speed of the car was 62 mph, the motorcycle was 78 mph and the bicycle was 15 mph.

Standard Abbreviations

The following abbreviations are considered by JMSACL to be STANDARD, and do not need to be described or expanded. **Statistical** - ANOVA - Analysis of Variance - CI - Confidence Interval - CV - Coefficient of Variation - p-value - Probability Value - SD - Standard Deviation - SEM - Standard Error of the Mean **Biological** - DNA - deoxyribonucleic acid - RNA - ribonucleic acid - mRNA - messenger RNA **Technical** - CID - Collision-Induced Dissociation - DART - Direct Analysis in Real Time - ESI - Electrospray Ionization - FT-ICR - Fourier Transform Ion Cyclotron Resonance - GC-MS - Gas Chromatography-Mass Spectrometry - GC-MSMS - LC-MS - Liquid Chromatography-Mass Spectrometry - LC-MSMS - MALDI - Matrix-Assisted Laser Desorption/Ionization - NMR - Nuclear Magnetic Resonance - QTOF - Quadrupole Time-of-Flight - SRM - Selected Reaction Monitoring - MRM - Multiple Reaction Monitoring - SIM - Selected Ion Monitoring - TIC - Total Ion Chromatogram **Other** - IRB - Institutional Review Board

---

Submission Checklist

1. __ Confirm that neither the manuscript nor any parts of its content are currently under consideration or published in another journal.
2. __ Declaration of Relevant Financial Interests
   1. __ Fill out the Worksheet and include with manuscript submission.
   2. __ Include a Declaration of Relevant Financial Interests statement in the body of the manuscript, with the title “Declaration of Relevant Financial Interests”, placed after the CRediT Author Statement (see 13 below) using the worksheet (linked above) to guide the language in the statement.
3.  
4.  

---

About

• JMSACL is the official journal of the 501c3 non-profit association, MSACL.
• Launched November 2016 as Clinical Mass Spectrometry.
• Journal name revised on January 2021 to JMSACL.

Insights

• Impact Factor: 3.1 (2023)
• Cite Score: 5.0 (2024)
• Acceptance Rate:  ~25%
• Avgerage Time to Publish: 150 days

Publishing Model

• All articles are published under the CC BY Open Access License.
• Archived in PubMed Central (PMC) and CLOCKSS.
• Unique Article Identifiers: DOI (Digital Object Identifier).
• Published as HTML and PDF.
• Published online as a continuous annual volume throughout the calendar year. Articles are made available as soon as they are ready to ensure that there are no unnecessary delays in making content publicly available. Special thematic collections are continuously coordinated and populated.

Peer Review Model

• Single-blind. Authors cannot see reviewers, but reviewers can see authors.

Publishing Fees

• $0* APC for MSACL members.
• $2200 APC for non-members.

Types of Papers

• Original Research,
• Mini-Reviews
• Reviews
• Short Reports (e.g., short original research, protocols, application notes, developed poster presentations)
• Case Studies
• Editorials

Indexed in

• Current Contents
• Clinical Medicine
• Directory of Open Access Journals (DOAJ)
• Embase
• Essential Science Indicators
• Google Scholar
• PubMed Central (PMC)
• Science Citation Index Expanded (SCIE)
• SCImago Journal Rank (SJR)
• Scopus
• SNIP

Author Information: See [author information](https://jmsacl.scholasticahq.com/for-authors)

Sponsors and Affiliated Institutions

JMSACL's scholarship is supported by funding from MSACL

---

Focus and Scope

The Journal of Mass Spectrometry and Advances in the Clinical Lab (JMSACL) is an open access journal that publishes peer-reviewed articles addressing mass spectrometry and  <b>OTHER</b> advances in Laboratory Medicine and Pathology with a focus on development of diagnostic and related applications, including data science, to improve patient outcomes and reduce healthcare costs. Submissions are <b>NOT restricted to mass spectrometry</b> as an analysis technique.

Beyond communication of the application of technologies in the routine clinical diagnostic setting, by publishing critically validated analytical protocols, the journal also addresses the translation of experimental techniques and analytical research into patient care, and the use of these technologies in clinical research and routine patient management. The scope of the journal is not restricted to any particular technology, but covers the entire range of technologies and advancements that are expected to impact the clinical lab.

The journal encourages submissions that have a clear path to patient care, including basic and translational research, and animal studies.

Subject areas covered by the journal include, but are not restricted to:

• Automation
• Clinical Studies and Implementation
• Cross-Technology Investigations
• Data Science
• Endocrinology
• Error Sources, Risk Assessment and Patient Safety
• Glycomics
• Harmonization and Standardization
• Imaging
• Instrumentation
• Lipidomics
• Metabolomics and Metabolic Analyses<
• Method Development and Validation
• Metrology
• Microbiology
• Neonatal Screening
• New Technologies
• Point-of-Care Technologies
• Protein Quantification
• Protein Variant Detection
• Proteomics
• Quality Management
• Reference Methods and Materials
• Regulatory Aspects in Diagnostic Applications
• Sample Preparation
• Separation Science
• Small Molecules<
• Spatialomics
• Therapeutic Drug Monitoring
• Toxicology

---

---

Peer Review

This journal operates a single anonymous peer review policy.

---

Licences

The following licences are allowed:

• Copyright
  © the author(s). All rights reserved.
• CC BY 4.0
  Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
• CC BY-ND 4.0
  Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
• CC BY-NC 4.0
  Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NonCommercial — You may not use the material for commercial purposes. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
• CC BY-NC-ND 4.0
  Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NonCommercial — You may not use the material for commercial purposes. NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
• CC BY-SA 4.0
  Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

---

---

Publication Fees

• $0* APC for MSACL members.
• $2200 APC for non-members.

---

Publication Cycle

Published online as a continuous annual volume throughout the calendar year. Articles are made available as soon as they are ready to ensure that there are no unnecessary delays in making content publicly available. Special thematic collections are continuously coordinated and populated.

---

Sections

Section or article type	Public Submissions	Peer Reviewed	Indexed
Article
Mini-Review

---